Press Releases

PTC Therapeutics, Inc. is committed to serving the interests of all our stakeholders.
Living with
Duchenne Muscular Dystrophy,
DANYA - Duchenne Muscular Dysthropy- Ukraine

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Sep 20, 2021 STRIDE Data Show Translarna™ Delays Loss of Ambulation by More Than Five Years in Boys with Nonsense Mutation Duchenne Muscular Dystrophy
- Translarna was seen to slow disease progression compared to standard of care alone - - Data from long-term, real-world results from 241 patients in the STRIDE* patient registry - SOUTH PLAINFIELD, N.J. , Sept. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc.
Sep 07, 2021 PTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient Community
- Patient Advocacy Organizations in Brazil and the U.K. Awarded Funding - SOUTH PLAINFIELD, N.J. , Sept. 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three recipients who will receive funding through the company's STRIVE Awards program.
Aug 27, 2021 PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences
SOUTH PLAINFIELD, N.J. , Aug. 27, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Morgan Stanley Virtual 19 th Annual Global Healthcare Conference Friday, September 10 th at 11:00 a.m.
Aug 23, 2021 PTC Therapeutics Announces Waylivra™ Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome
- Approval Addresses Unmet Needs of Patients with No Other Treatment Options - SOUTH PLAINFIELD, N.J. , Aug. 23, 2021 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved
Aug 23, 2021 Targeting the Putamen with Gene Therapy Leads to Sustained Improvements in Motor and Non-Motor Functions in Children with AADC Deficiency
- Commentary Published in the European Molecular Biology Organization Journal - SOUTH PLAINFIELD, N.J. , Aug. 23, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of a manuscript, "Gene Therapy in the Putamen for Curing AADC Deficiency and Parkinson's
Aug 20, 2021 PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , Aug. 20, 2021 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on Aug. 17, 2021, it approved non-statutory stock options to purchase an aggregate of 51,670 shares of its common stock and 19,755 restricted stock units ("RSUs"), each representing
Jul 29, 2021 PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results
- Total quarterly net revenue of $117 million; 55% increase over second quarter 2020 - - Raises 2021 DMD franchise revenue guidance to $370-$390M from $355-$375M - - Progress across robust clinical pipeline with 3 ongoing registration-directed trials - SOUTH PLAINFIELD, N.J.
Jul 28, 2021 Significant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Evrysdi™
- Results from Part 2 of FIREFISH pivotal study published in the New England Journal of Medicine - SOUTH PLAINFIELD, N.J. , July 28, 2021 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that results from Part 2 of the FIREFISH pivotal study were published in the New England
Jul 15, 2021 PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2021 Financial Results
SOUTH PLAINFIELD, N.J. , July 15, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2021 financial results and provide an update on the company's business and outlook on Thursday, July 29,
Jun 24, 2021 Results Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone
- Data presented at the 2021 Parent Project Muscular Dystrophy Annual Conference - SOUTH PLAINFIELD, N.J. , June 24, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented pooled placebo data from multiple studies in which the results confirmed the clinical benefit of EMFLAZA ®